Emad Tashkandi
Overview
Explore the profile of Emad Tashkandi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
84
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tashkandi E
Cancer Manag Res
. 2025 Mar;
17:419-428.
PMID: 40046653
Background: Real-world data on treatment patterns and survival outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) remain limited. This study aims to characterize treatment sequencing, duration across lines of therapy, and...
2.
Aseafan M, Alfakeeh A, Tashkandi E, Mahrous M, Alghamdi M, Alshamsan B, et al.
BMC Cancer
. 2025 Jan;
25(1):7.
PMID: 39754118
Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited treatment options yielding poor outcomes. This study aimed to evaluate the real-world clinical characteristics, treatment patterns,...
3.
Khizanah R, Tashkandi E, Jaffal M, Alsaedi M, Al-Ahmdi Y, Almehmadi A, et al.
Saudi Med J
. 2024 Jun;
45(6):639-642.
PMID: 38830651
Objectives: To describe the current real-world treatment landscape, sequence of therapies, and outcomes in patients with prostate cancer (PC). Methods: A retrospective cohort study for PC patients diagnosed at King...
4.
Tashkandi E
Case Rep Oncol
. 2023 Nov;
16(1):676-680.
PMID: 37933316
Testicular adenomatoid tumor is very rare. More understanding of the tumor and treatment is required for better outcomes. A 63-year-old man visited a urologist for staghorn calculus. During follow-up, he...
5.
Alqurashi R, Tamim H, Alsubhi Z, Alzahrani A, Tashkandi E
Cureus
. 2022 Nov;
14(10):e30652.
PMID: 36439565
Tumor lysis syndrome (TLS) in patients with solid tumors is a rare and potentially fatal condition associated with anti-cancer treatment. Its outcome depends on awareness, identification of high-risk patients, and...
6.
Babkoor A, Aljabri Y, Alzubaidi A, Alhazmi R, Alsaedi Z, Alghamdi F, et al.
Cureus
. 2022 Mar;
14(1):e21560.
PMID: 35233298
Novel oral anti-androgens (NOAAs) represent a new class of drugs that are being approved for prostate cancer. However, fatigue and anemia are among the most common treatment-related symptoms. Hence, we...
7.
Rafii S, Tashkandi E, Bukhari N, Al-Shamsi H
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205694
Cancer is considered by not only multiple genetic but also epigenetic amendments that drive malignant cell propagation and consult chemo-resistance. The ability to correct or ablate such mutations holds enormous...
8.
Elsamany S, Elsisi G, Mohamed Hassanin F, Saleh K, Tashkandi E
Value Health Reg Issues
. 2021 Nov;
28:67-75.
PMID: 34801961
Objectives: Our objective was to evaluate the cost-effectiveness of first-line cetuximab in relation to primary tumor location and after resection from the perspective of the Saudi healthcare system over a...
9.
Elsamany S, Elbaiomy M, Zeeneldin A, Tashkandi E, Hassanin F, Abdelhafeez N, et al.
JMIR Cancer
. 2021 Nov;
7(4):e27073.
PMID: 34726611
Background: Management of patients with cancer in the current era of the COVID-19 pandemic poses a significant challenge to health care systems. Breast cancer is the most common cancer internationally....
10.
Bukhari N, Alshangiti A, Tashkandi E, Algarni M, Al-Shamsi H, Al-Khallaf H
Clin Pract
. 2021 Aug;
11(3):467-471.
PMID: 34449540
Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report cases from our institute with colorectal cancer who experienced severe toxicities...